许昆林王新伟会见知名医药企业投资考察团一行

Core Viewpoint - Liaoning Province is actively engaging with a delegation of renowned pharmaceutical companies to enhance cooperation and investment in the region's pharmaceutical industry, aiming to establish itself as a key hub for pharmaceutical innovation by 2030 [1] Group 1: Investment and Cooperation - The investment delegation consists of representatives from 12 Fortune 500 pharmaceutical companies and 6 well-known domestic and international pharmaceutical enterprises [1] - The delegation aims to leverage this visit to foster communication and collaboration, seeking to identify synergies and promote high-quality projects and innovative products in Liaoning [1] Group 2: Industry Development - Liaoning is a major production area for traditional Chinese medicine, particularly "Northern Medicine," with several categories ranking first in national output [1] - The province has a comprehensive pharmaceutical industry structure, including research, manufacturing, distribution, and services, supported by numerous research institutions and innovation platforms [1] - The provincial government is prioritizing biomedicine and advanced medical equipment as key emerging industries, with plans to establish a full-chain support mechanism for pharmaceutical innovation [1] Group 3: Future Goals - By 2030, Liaoning aims to become a leading center for pharmaceutical innovation in Northeast China and a production base for critical pharmaceutical raw materials and high-end medical devices [1]